Depomed settles with generics over Gralise dispute
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
The settlements with Incepta and Zydus allow the companies to start selling gabapentin tablets on January 1, 2024.
Gralise is used to treat pain after having shingles. Sales of the product totalled $36 million in 2013.
Depomed filed patent infringement cases against Actavis, Incepta and Zydus at the US District Court for the District of New Jersey in 2012, after the generic drug makers filed Abbreviated New Drug Applications with the US Food and Drug Administration to market generic versions of Gralise.
Depomed’s litigation with Actavis is still pending.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk